{"id":19,"date":"2020-01-21T14:35:23","date_gmt":"2020-01-21T14:35:23","guid":{"rendered":"https:\/\/www.almacgroup.com\/discovery\/?page_id=19"},"modified":"2026-03-12T15:10:37","modified_gmt":"2026-03-12T15:10:37","slug":"meet-the-team","status":"publish","type":"page","link":"https:\/\/www.almacgroup.com\/discovery\/about\/meet-the-team\/","title":{"rendered":"Leadership Team"},"content":{"rendered":"            <article class=\"c-team-member\">\n                            <aside>\n                    <img decoding=\"async\" data-src=\"https:\/\/www.almacgroup.com\/discovery\/wp-content\/uploads\/sites\/2\/2020\/03\/Stephen-Barr1-200x200-1.jpg\" alt=\"\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" class=\"lazyload\" style=\"--smush-placeholder-width: 200px; --smush-placeholder-aspect-ratio: 200\/200;\"><noscript><img decoding=\"async\" src=\"https:\/\/www.almacgroup.com\/discovery\/wp-content\/uploads\/sites\/2\/2020\/03\/Stephen-Barr1-200x200-1.jpg\" alt=\"\"><\/noscript>\n                <\/aside>\n                        <section>\n                <h4>Stephen Barr<\/h4>\n                <h5>President &#038; Managing Director, Almac Discovery<\/h5>\n                <div class=\"c-team-member__text more\">Stephen is a member of the Almac Group Executive Management and President and Managing Director of both Almac Discovery and Almac Sciences. He was instrumental in establishing Almac Discovery and has had overall responsibility for strategic, financial and operational leadership ever since.<br \/>\r\n<br \/>\r\nIn 2004, Stephen saw the opportunity to acquire Albachem for Almac Sciences Division which subsequently enabled key personnel to join Almac Discovery to strengthen our peptide and protein chemistry capabilities and support our first clinical candidate ALM201. Later, Stephen set up the unique relationship with the Cancer Centre for Research and Cellular Biology (CCRCB) at Queen\u2019s University which seeks to consolidate Discovery\u2019s oncology focus.  Stephen has a Ph.D in synthetic chemistry.<\/div>\n            <\/section>\n        <\/article>\n\n    \n\n            <article class=\"c-team-member\">\n                            <aside>\n                    <img decoding=\"async\" data-src=\"https:\/\/www.almacgroup.com\/discovery\/wp-content\/uploads\/sites\/2\/2020\/03\/Tim_Harrison-200x200-1.png\" alt=\"\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" class=\"lazyload\" style=\"--smush-placeholder-width: 200px; --smush-placeholder-aspect-ratio: 200\/200;\"><noscript><img decoding=\"async\" src=\"https:\/\/www.almacgroup.com\/discovery\/wp-content\/uploads\/sites\/2\/2020\/03\/Tim_Harrison-200x200-1.png\" alt=\"\"><\/noscript>\n                <\/aside>\n                        <section>\n                <h4>Tim Harrison<\/h4>\n                <h5>Vice President, Discovery Chemistry<\/h5>\n                <div class=\"c-team-member__text more\">After obtaining a First Class degree in Chemistry and Ph.D. in organic chemistry at Nottingham University, and completing postdoctoral studies at the University of California, Irvine, Tim joined Merck\u2019s Neuroscience Research Centre where he was Director, Medicinal Chemistry Department. Whilst at Merck, Tim was part of the team which discovered the marketed Substance P antagonist Aprepitant (Emend). He was subsequently involved in the establishment of Almac Discovery, where he holds the position of Vice President, Drug Discovery.<br \/>\r\n<br \/>\r\nTim also holds a Chair position at the Patrick G Johnston Centre for Cancer Research at Queen\u2019s University, Belfast, where he is the McClay Professor of Medicinal Chemistry. His research focuses on new therapeutic approaches to exploit apoptosis.<br \/>\r\n<\/div>\n            <\/section>\n        <\/article>\n\n    \n\n            <article class=\"c-team-member\">\n                            <aside>\n                    <img decoding=\"async\" data-src=\"https:\/\/www.almacgroup.com\/discovery\/wp-content\/uploads\/sites\/2\/2026\/03\/GCotton-200x200-1.jpg\" alt=\"\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" class=\"lazyload\" style=\"--smush-placeholder-width: 200px; --smush-placeholder-aspect-ratio: 200\/200;\"><noscript><img decoding=\"async\" src=\"https:\/\/www.almacgroup.com\/discovery\/wp-content\/uploads\/sites\/2\/2026\/03\/GCotton-200x200-1.jpg\" alt=\"\"><\/noscript>\n                <\/aside>\n                        <section>\n                <h4>Graham Cotton<\/h4>\n                <h5>Vice President, Protein Therapeutics<\/h5>\n                <div class=\"c-team-member__text more\">Having received a First Class degree in Chemistry from Durham University, Graham obtained his Ph.D. from the University of Edinburgh, working on engineered protein therapeutics for HIV, and continued these interdisciplinary studies as a postdoctoral researcher at the University\u2019s Medical School.<br \/>\r\n<br \/>\r\nHe then spent several years at Rockefeller University New York, as a Burroughs Wellcome Research Fellow, developing novel protein engineering technologies to study oncogenic signalling pathways. Graham then returned to the UK and held senior positions at several biotech companies before joining Almac Discovery in 2013 to lead their protein therapeutics programmes. These drug discovery efforts focus on the development of next generation bispecific antibody drug conjugates.<br \/>\r\n<br \/>\r\nGraham also holds an Honorary position at The Johnston Cancer Research Centre at Queen\u2019s University Belfast.<br \/>\r\n<br \/>\r\n<br \/>\r\n<\/div>\n            <\/section>\n        <\/article>\n\n    \n\n            <article class=\"c-team-member\">\n                            <aside>\n                    <img decoding=\"async\" data-src=\"https:\/\/www.almacgroup.com\/discovery\/wp-content\/uploads\/sites\/2\/2026\/03\/Aaron-Cranston-200x200-1.jpg\" alt=\"\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" class=\"lazyload\" style=\"--smush-placeholder-width: 200px; --smush-placeholder-aspect-ratio: 200\/183;\"><noscript><img decoding=\"async\" src=\"https:\/\/www.almacgroup.com\/discovery\/wp-content\/uploads\/sites\/2\/2026\/03\/Aaron-Cranston-200x200-1.jpg\" alt=\"\"><\/noscript>\n                <\/aside>\n                        <section>\n                <h4>Aaron Cranston<\/h4>\n                <h5>Director of Translational Research<\/h5>\n                <div class=\"c-team-member__text more\">Aaron joined Almac Discovery in 2016 from Mission Therapeutics and has responsibility for translational research activities. He has over 20 years\u2019 experience in preclinical oncology including previous positions at leading biotech\u2019s, a global pharma and two specialist oncology CROs.  At KuDOS Pharmaceuticals (acquired by AstraZeneca), he led the translational biology and tumour pharmacology team for 5 novel DDR projects transitioning into clinical development, most notably making major contributions to the PARP inhibitor programme which led to olaparib (Lynparza\u00ae), now an approved, first-in-class, marketed treatment for BRCA-mutant cancers and the first proof-of-concept for synthetic lethality as a therapeutic approach.<br \/>\r\n<br \/>\r\nAaron carried out his post-doctoral research at the Kimmel Cancer Center, Philadelphia and returned to the UK to lead the MEN2 cancer group at the University of Cambridge before transitioning into industry.<br \/>\r\n<br \/>\r\nHe holds a First-Class degree in Genetics and a Ph.D. in Cancer Genetics from Queen\u2019s University Belfast. <\/div>\n            <\/section>\n        <\/article>\n\n    \n\n            <article class=\"c-team-member\">\n                            <aside>\n                    <img decoding=\"async\" data-src=\"https:\/\/www.almacgroup.com\/discovery\/wp-content\/uploads\/sites\/2\/2020\/03\/Colin_Odowd-200x200-1.png\" alt=\"\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" class=\"lazyload\" style=\"--smush-placeholder-width: 200px; --smush-placeholder-aspect-ratio: 200\/200;\"><noscript><img decoding=\"async\" src=\"https:\/\/www.almacgroup.com\/discovery\/wp-content\/uploads\/sites\/2\/2020\/03\/Colin_Odowd-200x200-1.png\" alt=\"\"><\/noscript>\n                <\/aside>\n                        <section>\n                <h4>Colin O\u2019Dowd<\/h4>\n                <h5>Vice President, Medicinal Chemistry<\/h5>\n                <div class=\"c-team-member__text more\">Colin leads the Medicinal Chemistry, ADMET and CADD teams at Almac Discovery, bringing over two decades of industry experience across drug discovery and synthetic chemistry development. He and his teams have played a pivotal role in advancing Almac Discovery\u2019s kinase, deubiquitylating enzyme (DUB) and induced proximity programmes.<br \/>\r\n<br \/>\r\nColin has also been instrumental in the establishment of the Future Medicines Institute (FMI) and the Northern Ireland Chemoproteomics Centre-of-Excellence.<br \/>\r\n<br \/>\r\nHe holds a Ph.D. in synthetic organic chemistry from Queen\u2019s University Belfast<br \/>\r\n<br \/>\r\n<\/div>\n            <\/section>\n        <\/article>\n\n    \n\n            <article class=\"c-team-member\">\n                            <aside>\n                    <img decoding=\"async\" data-src=\"https:\/\/www.almacgroup.com\/discovery\/wp-content\/uploads\/sites\/2\/2026\/03\/Natalie-Page.jpg\" alt=\"\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" class=\"lazyload\" style=\"--smush-placeholder-width: 200px; --smush-placeholder-aspect-ratio: 200\/197;\"><noscript><img decoding=\"async\" src=\"https:\/\/www.almacgroup.com\/discovery\/wp-content\/uploads\/sites\/2\/2026\/03\/Natalie-Page.jpg\" alt=\"\"><\/noscript>\n                <\/aside>\n                        <section>\n                <h4>Natalie Page<\/h4>\n                <h5>Head of Biology<\/h5>\n                <div class=\"c-team-member__text more\">Natalie joined Almac Discovery in 2008 and now leads the strategic development and scientific execution of the company\u2019s biology portfolio. Together with her team, she has played a pivotal role in advancing multiple assets from target validation through to clinical translation. <br \/>\r\n<br \/>\r\nHer scientific interests and expertise centre on the ubiquitin\u2013proteasome system, spanning early stage discovery of DUB inhibitors, emerging induced\u2011proximity therapeutic modalities and advanced chemical biology platforms. Fostering strong collaborative networks with academic partners, Natalie has also been central to establishing the Future Medicines Institute (FMI) and the Northern Ireland Chemoproteomics Centre of Excellence.  <br \/>\r\n<br \/>\r\nShe holds a Ph.D. in experimental cancer therapeutics from Queen\u2019s University Belfast. <\/div>\n            <\/section>\n        <\/article>\n\n    \n\n            <article class=\"c-team-member\">\n                            <aside>\n                    <img decoding=\"async\" data-src=\"https:\/\/www.almacgroup.com\/discovery\/wp-content\/uploads\/sites\/2\/2026\/03\/MWappett-200x200-1.jpg\" alt=\"\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" class=\"lazyload\" style=\"--smush-placeholder-width: 200px; --smush-placeholder-aspect-ratio: 200\/200;\"><noscript><img decoding=\"async\" src=\"https:\/\/www.almacgroup.com\/discovery\/wp-content\/uploads\/sites\/2\/2026\/03\/MWappett-200x200-1.jpg\" alt=\"\"><\/noscript>\n                <\/aside>\n                        <section>\n                <h4>Mark Wappett<\/h4>\n                <h5>Head of Bioinformatics and Data Science<\/h5>\n                <div class=\"c-team-member__text more\">Mark joined Almac Discovery in 2015 to establish a bioinformatics capability within the company and has responsibility for developing the bioinformatics and data science functions.<br \/>\r\n<br \/>\r\nPrior to joining Almac Discovery, Mark worked for AstraZeneca supporting pre-clinical drug discovery where he developed a research interest in computational approaches to detecting synthetic lethality.  Mark previously worked at CRUK-Manchester where he developed microarray and next-generation sequencing tools.  Mark has a Ph.D. in Bioinformatics from Queen\u2019s University Belfast.<br \/>\r\n<\/div>\n            <\/section>\n        <\/article>\n\n    \n\n            <article class=\"c-team-member\">\n                            <aside>\n                    <img decoding=\"async\" data-src=\"https:\/\/www.almacgroup.com\/discovery\/wp-content\/uploads\/sites\/2\/2026\/03\/Hozefa-Amijee.jpg\" alt=\"\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" class=\"lazyload\" style=\"--smush-placeholder-width: 200px; --smush-placeholder-aspect-ratio: 200\/197;\"><noscript><img decoding=\"async\" src=\"https:\/\/www.almacgroup.com\/discovery\/wp-content\/uploads\/sites\/2\/2026\/03\/Hozefa-Amijee.jpg\" alt=\"\"><\/noscript>\n                <\/aside>\n                        <section>\n                <h4>Hozefa Amijee<\/h4>\n                <h5>Business Development and Licensing Manager<\/h5>\n                <div class=\"c-team-member__text more\">Hozefa has 20+ years\u2019 experience in the life sciences industry across Europe, North America and APAC. Prior to joining Almac Discovery, Hozefa was Head of Business Development at Ubiquigent, where he led commercial strategy and execution, and at Cellesce Ltd, in Cardiff. Hozefa has also held scientific roles at both RxCelerate and Senexis in Cambridge. He holds a BSc in Biochemistry from UMIST, and a Ph.D. in Biochemistry from the University of Manchester.<\/div>\n            <\/section>\n        <\/article>\n\n    ","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":11,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-19","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.3.1 (Yoast SEO v26.3) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Leadership Team - Discovery<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.almacgroup.com\/discovery\/about\/meet-the-team\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Leadership Team\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.almacgroup.com\/discovery\/about\/meet-the-team\/\" \/>\n<meta property=\"og:site_name\" content=\"Discovery\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-12T15:10:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.almacgroup.com\/discovery\/wp-content\/uploads\/sites\/2\/2020\/11\/Almac_Logo.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"334\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.almacgroup.com\/discovery\/about\/meet-the-team\/\",\"url\":\"https:\/\/www.almacgroup.com\/discovery\/about\/meet-the-team\/\",\"name\":\"Leadership Team - Discovery\",\"isPartOf\":{\"@id\":\"https:\/\/www.almacgroup.com\/discovery\/#website\"},\"datePublished\":\"2020-01-21T14:35:23+00:00\",\"dateModified\":\"2026-03-12T15:10:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.almacgroup.com\/discovery\/about\/meet-the-team\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.almacgroup.com\/discovery\/about\/meet-the-team\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.almacgroup.com\/discovery\/about\/meet-the-team\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Almac Discovery\",\"item\":\"https:\/\/www.almacgroup.com\/discovery\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"About Us\",\"item\":\"https:\/\/www.almacgroup.com\/discovery\/about\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Leadership Team\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.almacgroup.com\/discovery\/#website\",\"url\":\"https:\/\/www.almacgroup.com\/discovery\/\",\"name\":\"Discovery\",\"description\":\"Almac Group\",\"publisher\":{\"@id\":\"https:\/\/www.almacgroup.com\/discovery\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.almacgroup.com\/discovery\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.almacgroup.com\/discovery\/#organization\",\"name\":\"Almac Group Ltd\",\"url\":\"https:\/\/www.almacgroup.com\/discovery\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.almacgroup.com\/discovery\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.almacgroup.com\/discovery\/wp-content\/uploads\/sites\/2\/2020\/04\/almac-logo-with-strapline.jpg\",\"contentUrl\":\"https:\/\/www.almacgroup.com\/discovery\/wp-content\/uploads\/sites\/2\/2020\/04\/almac-logo-with-strapline.jpg\",\"width\":643,\"height\":296,\"caption\":\"Almac Group Ltd\"},\"image\":{\"@id\":\"https:\/\/www.almacgroup.com\/discovery\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Leadership Team - Discovery","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.almacgroup.com\/discovery\/about\/meet-the-team\/","og_locale":"en_GB","og_type":"article","og_title":"Leadership Team","og_url":"https:\/\/www.almacgroup.com\/discovery\/about\/meet-the-team\/","og_site_name":"Discovery","article_modified_time":"2026-03-12T15:10:37+00:00","og_image":[{"width":640,"height":334,"url":"https:\/\/www.almacgroup.com\/discovery\/wp-content\/uploads\/sites\/2\/2020\/11\/Almac_Logo.jpeg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.almacgroup.com\/discovery\/about\/meet-the-team\/","url":"https:\/\/www.almacgroup.com\/discovery\/about\/meet-the-team\/","name":"Leadership Team - Discovery","isPartOf":{"@id":"https:\/\/www.almacgroup.com\/discovery\/#website"},"datePublished":"2020-01-21T14:35:23+00:00","dateModified":"2026-03-12T15:10:37+00:00","breadcrumb":{"@id":"https:\/\/www.almacgroup.com\/discovery\/about\/meet-the-team\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.almacgroup.com\/discovery\/about\/meet-the-team\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.almacgroup.com\/discovery\/about\/meet-the-team\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Almac Discovery","item":"https:\/\/www.almacgroup.com\/discovery\/"},{"@type":"ListItem","position":2,"name":"About Us","item":"https:\/\/www.almacgroup.com\/discovery\/about\/"},{"@type":"ListItem","position":3,"name":"Leadership Team"}]},{"@type":"WebSite","@id":"https:\/\/www.almacgroup.com\/discovery\/#website","url":"https:\/\/www.almacgroup.com\/discovery\/","name":"Discovery","description":"Almac Group","publisher":{"@id":"https:\/\/www.almacgroup.com\/discovery\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.almacgroup.com\/discovery\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/www.almacgroup.com\/discovery\/#organization","name":"Almac Group Ltd","url":"https:\/\/www.almacgroup.com\/discovery\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.almacgroup.com\/discovery\/#\/schema\/logo\/image\/","url":"https:\/\/www.almacgroup.com\/discovery\/wp-content\/uploads\/sites\/2\/2020\/04\/almac-logo-with-strapline.jpg","contentUrl":"https:\/\/www.almacgroup.com\/discovery\/wp-content\/uploads\/sites\/2\/2020\/04\/almac-logo-with-strapline.jpg","width":643,"height":296,"caption":"Almac Group Ltd"},"image":{"@id":"https:\/\/www.almacgroup.com\/discovery\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.almacgroup.com\/discovery\/wp-json\/wp\/v2\/pages\/19","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.almacgroup.com\/discovery\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.almacgroup.com\/discovery\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.almacgroup.com\/discovery\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.almacgroup.com\/discovery\/wp-json\/wp\/v2\/comments?post=19"}],"version-history":[{"count":20,"href":"https:\/\/www.almacgroup.com\/discovery\/wp-json\/wp\/v2\/pages\/19\/revisions"}],"predecessor-version":[{"id":1481,"href":"https:\/\/www.almacgroup.com\/discovery\/wp-json\/wp\/v2\/pages\/19\/revisions\/1481"}],"up":[{"embeddable":true,"href":"https:\/\/www.almacgroup.com\/discovery\/wp-json\/wp\/v2\/pages\/11"}],"wp:attachment":[{"href":"https:\/\/www.almacgroup.com\/discovery\/wp-json\/wp\/v2\/media?parent=19"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}